A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety and immunogenicity of BAT1806 SC with Tocilizumab in healthy Chinese male subjects
{{output}}
Background: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the tocilizumab biosimilar, BAT1806 SC (Tocilizumab biosimilar, Subcutaneous Injection), with Tocilizumab (RoActemra®) in healthy Chinese m... ...
